NOTE 8. GOODWILL AND OTHER INTANGIBLE ASSETS



GOODWILL (In millions)	January 1, 2019		Acquisitions		Dispositions, currency exchange and other			Balance at March 31, 2019

Power	$	1,772	$	—	$	14		$	1,787
Renewable Energy	3,971		—		23			3,994
Aviation	9,839		—		2			9,841
Oil & Gas	24,455		—		60			24,514
Healthcare	17,226		—		(5,500		)	11,727
Capital	904		—		(26		)	878
Corporate	563		—		(109		)	454
Total	$	58,730	$	—	$	(5,536	)	$	53,194

Goodwill balances decreased primarily as a result of transferring our BioPharma business within our Healthcare segment to held for sale of $5,548 million.

In assessing the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates, we consider all available evidence, including (i) the results of our impairment testing from the most recent testing date (in particular, the magnitude of the excess of fair value over carrying value observed), (ii) downward revisions to internal forecasts or decreases in market multiples (and the magnitude thereof), if any, and (iii) declines in market capitalization below book value (and the magnitude and duration of those declines), if any. In the first quarter of 2019, we performed a qualitative review of our reporting units in our BHGE segment, Grid reporting unit in our Power segment, Hydro reporting unit in our Renewable Energy segment, and our Additive reporting unit in our Aviation segment. We did not identify any reporting units that required an interim impairment test.

As of March 31, 2019, we believe goodwill is recoverable for all of our reporting units. While the goodwill in our Grid reporting unit, Hydro reporting unit, and Oil & Gas reporting units is not currently impaired, the power and oil and gas markets continue to be challenging and there can be no assurances that goodwill will not be impaired in future periods as a result of sustained declines in BHGE share price or any future declines in macroeconomic or business conditions affecting these reporting units. In addition, we will continue to measure our ability to meet our cash flow forecasts and to monitor the operating results of our Additive reporting unit, which could impact the fair value of this reporting unit in the future.



OTHER INTANGIBLE ASSETS - NET (In millions)	March 31, 2019		December 31, 2018

Intangible assets subject to amortization	$	14,812	$	15,675
Indefinite-lived intangible assets(a)	2,242		2,222
Total	$	17,053	$	17,897


(a)	Indefinite-lived intangible assets comprises trademarks/trade names in our Oil & Gas segment.

Intangible assets subject to amortization decreased in the first quarter of 2019, primarily as a result of amortization, and the transfer of BioPharma within our Healthcare segment to held for sale of $524 million. Consolidated amortization expense was $463 million and $602 million in the three months ended March 31, 2019 and 2018, respectively.